Multiple Sclerosis Journal:脑桥周围病变的定位是鉴别MS与小血管病的良好指标

2021-06-30 MedSci原创 MedSci原创

脑桥周围病变的定位是鉴别MS与小血管病的良好指标。

多发性硬化症(MS)中描述了桥脑周围的病变,理论上,由于丰富的血管化,该区域不易发生血管危险因子(VRF)相关的小血管病(SVD)。相反,中央桥由穿通端小动脉供应,易发生缺血缺氧和脱髓鞘,这是VRF-SVD患者T2磁共振成像(MRI)高信号的基础。然而,这些假设是基于有限的观察和这些标志物在鉴别MS和SVD相关病变中的作用还没有得到验证。 Ruth Geraldes等探讨了VRFs和MS是否与位于不同位置的脑桥病变相关,定义为中心或周围,并确定这些位置的脑桥病变对MS和VRF-SVD的特异性。研究结果发表在Multiple Sclerosis Journal杂志。 将多发性硬化(MS)与血管危险因素(VRF)-小血管疾病(SVD)区分开来是一个具有挑战性的问题。 为了确定脑桥病变的位置是否是鉴别MS和VRF-SVD的有用指标,该研究对93例无VRF的MS患者、108例VRF的MS患者和43例VRF的非MS患者的脑桥病变进行了脑磁共振(MRI)分类。 (a) 如果脑桥病变位于脑桥中点(从基底沟到后正中沟的一条线的中点,如轴向切面所见)半径为1.0 cm,则为中央型;如果超出该半径,则为外

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644896, encodeId=0ca01644896b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon May 09 05:12:30 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715858, encodeId=f1561e15858b3, content=<a href='/topic/show?id=441b4e17253' target=_blank style='color:#2F92EE;'>#小血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47172, encryptionId=441b4e17253, topicName=小血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956e32082497, createdName=clmlylxy, createdTime=Thu Jun 09 08:12:30 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947339, encodeId=7f6a194e339df, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 25 13:12:30 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010690, encodeId=a29720106907c, content=<a href='/topic/show?id=6212866427d' target=_blank style='color:#2F92EE;'>#良好指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86642, encryptionId=6212866427d, topicName=良好指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Sep 30 11:12:30 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695653, encodeId=322b16956535b, content=<a href='/topic/show?id=d7298488274' target=_blank style='color:#2F92EE;'>#脑桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84882, encryptionId=d7298488274, topicName=脑桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937429851027, createdName=amy0560, createdTime=Mon Feb 28 04:12:30 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364744, encodeId=b8771364e4472, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 02 14:12:30 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644896, encodeId=0ca01644896b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon May 09 05:12:30 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715858, encodeId=f1561e15858b3, content=<a href='/topic/show?id=441b4e17253' target=_blank style='color:#2F92EE;'>#小血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47172, encryptionId=441b4e17253, topicName=小血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956e32082497, createdName=clmlylxy, createdTime=Thu Jun 09 08:12:30 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947339, encodeId=7f6a194e339df, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 25 13:12:30 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010690, encodeId=a29720106907c, content=<a href='/topic/show?id=6212866427d' target=_blank style='color:#2F92EE;'>#良好指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86642, encryptionId=6212866427d, topicName=良好指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Sep 30 11:12:30 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695653, encodeId=322b16956535b, content=<a href='/topic/show?id=d7298488274' target=_blank style='color:#2F92EE;'>#脑桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84882, encryptionId=d7298488274, topicName=脑桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937429851027, createdName=amy0560, createdTime=Mon Feb 28 04:12:30 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364744, encodeId=b8771364e4472, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 02 14:12:30 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644896, encodeId=0ca01644896b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon May 09 05:12:30 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715858, encodeId=f1561e15858b3, content=<a href='/topic/show?id=441b4e17253' target=_blank style='color:#2F92EE;'>#小血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47172, encryptionId=441b4e17253, topicName=小血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956e32082497, createdName=clmlylxy, createdTime=Thu Jun 09 08:12:30 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947339, encodeId=7f6a194e339df, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 25 13:12:30 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010690, encodeId=a29720106907c, content=<a href='/topic/show?id=6212866427d' target=_blank style='color:#2F92EE;'>#良好指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86642, encryptionId=6212866427d, topicName=良好指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Sep 30 11:12:30 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695653, encodeId=322b16956535b, content=<a href='/topic/show?id=d7298488274' target=_blank style='color:#2F92EE;'>#脑桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84882, encryptionId=d7298488274, topicName=脑桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937429851027, createdName=amy0560, createdTime=Mon Feb 28 04:12:30 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364744, encodeId=b8771364e4472, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 02 14:12:30 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1644896, encodeId=0ca01644896b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon May 09 05:12:30 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715858, encodeId=f1561e15858b3, content=<a href='/topic/show?id=441b4e17253' target=_blank style='color:#2F92EE;'>#小血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47172, encryptionId=441b4e17253, topicName=小血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956e32082497, createdName=clmlylxy, createdTime=Thu Jun 09 08:12:30 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947339, encodeId=7f6a194e339df, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 25 13:12:30 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010690, encodeId=a29720106907c, content=<a href='/topic/show?id=6212866427d' target=_blank style='color:#2F92EE;'>#良好指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86642, encryptionId=6212866427d, topicName=良好指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Sep 30 11:12:30 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695653, encodeId=322b16956535b, content=<a href='/topic/show?id=d7298488274' target=_blank style='color:#2F92EE;'>#脑桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84882, encryptionId=d7298488274, topicName=脑桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937429851027, createdName=amy0560, createdTime=Mon Feb 28 04:12:30 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364744, encodeId=b8771364e4472, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 02 14:12:30 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1644896, encodeId=0ca01644896b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon May 09 05:12:30 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715858, encodeId=f1561e15858b3, content=<a href='/topic/show?id=441b4e17253' target=_blank style='color:#2F92EE;'>#小血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47172, encryptionId=441b4e17253, topicName=小血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956e32082497, createdName=clmlylxy, createdTime=Thu Jun 09 08:12:30 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947339, encodeId=7f6a194e339df, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 25 13:12:30 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010690, encodeId=a29720106907c, content=<a href='/topic/show?id=6212866427d' target=_blank style='color:#2F92EE;'>#良好指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86642, encryptionId=6212866427d, topicName=良好指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Sep 30 11:12:30 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695653, encodeId=322b16956535b, content=<a href='/topic/show?id=d7298488274' target=_blank style='color:#2F92EE;'>#脑桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84882, encryptionId=d7298488274, topicName=脑桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937429851027, createdName=amy0560, createdTime=Mon Feb 28 04:12:30 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364744, encodeId=b8771364e4472, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 02 14:12:30 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
    2022-02-28 amy0560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1644896, encodeId=0ca01644896b3, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon May 09 05:12:30 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715858, encodeId=f1561e15858b3, content=<a href='/topic/show?id=441b4e17253' target=_blank style='color:#2F92EE;'>#小血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47172, encryptionId=441b4e17253, topicName=小血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=956e32082497, createdName=clmlylxy, createdTime=Thu Jun 09 08:12:30 CST 2022, time=2022-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947339, encodeId=7f6a194e339df, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 25 13:12:30 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010690, encodeId=a29720106907c, content=<a href='/topic/show?id=6212866427d' target=_blank style='color:#2F92EE;'>#良好指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86642, encryptionId=6212866427d, topicName=良好指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Sep 30 11:12:30 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695653, encodeId=322b16956535b, content=<a href='/topic/show?id=d7298488274' target=_blank style='color:#2F92EE;'>#脑桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84882, encryptionId=d7298488274, topicName=脑桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937429851027, createdName=amy0560, createdTime=Mon Feb 28 04:12:30 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364744, encodeId=b8771364e4472, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 02 14:12:30 CST 2021, time=2021-07-02, status=1, ipAttribution=)]
    2021-07-02 lsndxfj

相关威廉亚洲官网

Radiology:人工智能在髋关节骨关节炎影像学特征严重程度分级中的应用

骨关节炎是最常见的慢性疾病之一,全世界有超过2.3亿人受其影响。骨关节炎是一种全关节疾病,最常见于中老年人群的膝关节和髋关节。

经典的胃肠道疾病影像学诊断经验

经典的胃肠道疾病影像学诊断经验

新型冠状病毒临床细胞因子风暴的特点、影像学特征

细胞因子风暴综合征(Cytokine Storm Syndrome,CSS)细胞因子风暴综合征最早1952年被Farquhar和Claireaux在家族性噬血细胞淋巴组织细胞增生症(fHLH)描述。在之后的五十年里研究并不多。直到2002年SARS开始,CSS引起多器官功能不全(MOF),导致极高的致死率,才再次引起了广泛关注。之后H7N9,H5N1,包括最近的2019-nCov,都有不同程度的C

J Rheumatol:手部骨关节炎加速的特征:来自骨关节炎创议的数据

手部可以出现加速OA,尤其是常用于捏和精细运动技能的手指。

Arthritis Rheumatol:早期中轴型脊柱关节炎患者长期抗TNF治疗期间的骶髂关节结构损伤进展

长期抗TNF治疗似乎减缓了SIJ结构损伤的进展。CRP升高和MRI上存在骨炎与影像学骶髂关节炎的进展独立相关。

Radiology:遇到肺结节,仅观察肉眼征象已远远不够!

肺腺癌以其病理异质性和预后多变而著称。为了改进肺腺癌的分类,2015年世界卫生组织肺肿瘤分类推荐切除肺腺癌按最主要的组织学亚型分类。